Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate

Vibrio cholerae is the causative agent of cholera, which is commonly associated with high morbidity and mortality, and presents a major challenge to healthcare systems throughout the world. Lipopolysaccharide (LPS) is required for full protection against V. cholerae but can induce inflammation and s...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell research & therapy 2021-11, Vol.12 (1), p.564-564, Article 564
Main Authors: Bahroudi, Mahboube, Bakhshi, Bita, Soudi, Sara, Najar-Peerayeh, Shahin
Format: Article
Language:English
Subjects:
Analysis
Animal models
Animals
Antibodies
Antibodies, Bacterial
Antibody
Antigens
Antimicrobial agents
BLyS protein
Cholera
Cholera toxin
Culture Media, Conditioned - pharmacology
Cytokine
Cytokines
Cytotoxicity
Drug dosages
Drug resistance
Flow cytometry
Humans
Immune response
Immunity
Immunization
Immunoglobulin A
Immunoglobulin G
Immunomodulation
Inflammation
Inflammatory diseases
Interleukin 10
Interleukin 4
Interleukin 5
Interleukin 6
Lipopolysaccharides
Lipopolysaccharides - pharmacology
LPS
Lymphocytes B
Medical research
Medicine, Experimental
Mesenchymal Stem Cells
Mice
Mitogens
Morbidity
Saliva
Septic shock
Stem cell transplantation
Stem cells
Transforming growth factors
Tumor necrosis factor-α
Vaccines
Vibrio cholerae
Vibrio cholerae O1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3
cites cdi_FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3
container_end_page 564
container_issue 1
container_start_page 564
container_title Stem cell research & therapy
container_volume 12
creator Bahroudi, Mahboube
Bakhshi, Bita
Soudi, Sara
Najar-Peerayeh, Shahin
description Vibrio cholerae is the causative agent of cholera, which is commonly associated with high morbidity and mortality, and presents a major challenge to healthcare systems throughout the world. Lipopolysaccharide (LPS) is required for full protection against V. cholerae but can induce inflammation and septic shock. Mesenchymal stem cells (MSCs) are currently used to treat infectious and inflammatory diseases. Therefore, this study aimed to evaluate the immune-modulating effects of the LPS-MSC-conditioned medium (CM) on V. cholerae LPS immunization in a murine model. After preconditioning MSCs with LPS, mice were immunized intraperitoneally on days 0 and 14 with the following combinations: LPS + LPS-MSC-CM; detoxified LPS (DLPS) + MSC-CM; LPS + MSC sup; LPS; LPS-MSC-CM; MSC supernatant (MSC sup); and PBS. The mouse serum and saliva samples were collected to evaluate antibody (serum IgG and saliva IgA) and cytokine responses (TNF-α, IL-10, IL-6, TGF-β, IL-4, IL-5, and B-cell activating factor (BAFF)). The LPS + LPS-MSC-CM significantly increased total IgG and IgA compared to other combinations (P 
doi_str_mv 10.1186/s13287-021-02622-0
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d2a136b9d3f849d7b1b0e3851ad75473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A681251237</galeid><doaj_id>oai_doaj_org_article_d2a136b9d3f849d7b1b0e3851ad75473</doaj_id><sourcerecordid>A681251237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3</originalsourceid><addsrcrecordid>eNptkltr3DAQhU1paUKaP9CHYiiU9MGpLr6-FELoZSFQ6O1VjKXRWottbSU7dJ_7xzvOpuluqW3ZQvrmGJ05SfKcs0vO6_JN5FLUVcYEp1EKkbFHySmviiorCy4eH8xPkvMYN4wuKRkr86fJicwrKUTRnCa_VsMwj37wZu5h8mGXorWop5h6mw4YcdTdboA-jRMOqca-z7QfjZucH9EQYRykfkx7t_Vb3-8iaN1BcAYXge-uDc6nuvM9BsAUYgrpLSFuxFQD6RiY8FnyxEIf8fz-e5Z8e__u6_XH7ObTh9X11U2mS1FPWVW2tgBttalZIxhwkI1smppeFhhvaq0tMy2zCLWEoqhzrARCrnMoZC6sPEtWe13jYaO2wQ0QdsqDU3cLPqwVhMnpHpURwGXZNkbaOm9M1fKWoawLDqYqyDzServX2s4tmaBxnAL0R6LHO6Pr1Nrfqrooq6IsSeDiXiD4HzPGSQ0uLv7CiH6Oiroj6aEuEfryH3Tj5zCSVQvVUBCYkH-pNdAB3Gg9_VcvouqqrLmgJMiKqMv_UHQbHBx1Fq2j9aOC10cFxEz4c1rDHKNaffl8zL46YDuEfuqi7-clLPEYFHtQBx9jQPtgHGdqibfax1tRvNVdvBWjoheHlj-U_Amz_A2qyfSs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2599132023</pqid></control><display><type>article</type><title>Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bahroudi, Mahboube ; Bakhshi, Bita ; Soudi, Sara ; Najar-Peerayeh, Shahin</creator><creatorcontrib>Bahroudi, Mahboube ; Bakhshi, Bita ; Soudi, Sara ; Najar-Peerayeh, Shahin</creatorcontrib><description>Vibrio cholerae is the causative agent of cholera, which is commonly associated with high morbidity and mortality, and presents a major challenge to healthcare systems throughout the world. Lipopolysaccharide (LPS) is required for full protection against V. cholerae but can induce inflammation and septic shock. Mesenchymal stem cells (MSCs) are currently used to treat infectious and inflammatory diseases. Therefore, this study aimed to evaluate the immune-modulating effects of the LPS-MSC-conditioned medium (CM) on V. cholerae LPS immunization in a murine model. After preconditioning MSCs with LPS, mice were immunized intraperitoneally on days 0 and 14 with the following combinations: LPS + LPS-MSC-CM; detoxified LPS (DLPS) + MSC-CM; LPS + MSC sup; LPS; LPS-MSC-CM; MSC supernatant (MSC sup); and PBS. The mouse serum and saliva samples were collected to evaluate antibody (serum IgG and saliva IgA) and cytokine responses (TNF-α, IL-10, IL-6, TGF-β, IL-4, IL-5, and B-cell activating factor (BAFF)). The LPS + LPS-MSC-CM significantly increased total IgG and IgA compared to other combinations (P &lt; 0.001). TNF-α levels, in contrast to IL-10 and TGF-β, were reduced significantly in mice receiving the LPS + LPS-MSC-CM compared to mice receiving only LPS. IL-4, IL-5, and BAFF levels significantly increased in mice receiving increased doses of LPS + LPS-MSC-CM compared to those who received only LPS. The highest vibriocidal antibody titer (1:64) was observed in LPS + LPS-MSC-CM-immunized mice and resulted in a significant improvement in survival in infant mice infected by V. cholerae O1. The LPS-MSC-CM modulates the immune response to V. cholerae LPS by regulating inflammatory and anti-inflammatory responses and inducing vibriocidal antibodies, which protect neonate mice against V. cholerae infection.</description><identifier>ISSN: 1757-6512</identifier><identifier>EISSN: 1757-6512</identifier><identifier>DOI: 10.1186/s13287-021-02622-0</identifier><identifier>PMID: 34732259</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Animal models ; Animals ; Antibodies ; Antibodies, Bacterial ; Antibody ; Antigens ; Antimicrobial agents ; BLyS protein ; Cholera ; Cholera toxin ; Culture Media, Conditioned - pharmacology ; Cytokine ; Cytokines ; Cytotoxicity ; Drug dosages ; Drug resistance ; Flow cytometry ; Humans ; Immune response ; Immunity ; Immunization ; Immunoglobulin A ; Immunoglobulin G ; Immunomodulation ; Inflammation ; Inflammatory diseases ; Interleukin 10 ; Interleukin 4 ; Interleukin 5 ; Interleukin 6 ; Lipopolysaccharides ; Lipopolysaccharides - pharmacology ; LPS ; Lymphocytes B ; Medical research ; Medicine, Experimental ; Mesenchymal Stem Cells ; Mice ; Mitogens ; Morbidity ; Saliva ; Septic shock ; Stem cell transplantation ; Stem cells ; Transforming growth factors ; Tumor necrosis factor-α ; Vaccines ; Vibrio cholerae ; Vibrio cholerae O1</subject><ispartof>Stem cell research &amp; therapy, 2021-11, Vol.12 (1), p.564-564, Article 564</ispartof><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3</citedby><cites>FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3</cites><orcidid>0000-0002-7523-7905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567566/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2599132023?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34732259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bahroudi, Mahboube</creatorcontrib><creatorcontrib>Bakhshi, Bita</creatorcontrib><creatorcontrib>Soudi, Sara</creatorcontrib><creatorcontrib>Najar-Peerayeh, Shahin</creatorcontrib><title>Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate</title><title>Stem cell research &amp; therapy</title><addtitle>Stem Cell Res Ther</addtitle><description>Vibrio cholerae is the causative agent of cholera, which is commonly associated with high morbidity and mortality, and presents a major challenge to healthcare systems throughout the world. Lipopolysaccharide (LPS) is required for full protection against V. cholerae but can induce inflammation and septic shock. Mesenchymal stem cells (MSCs) are currently used to treat infectious and inflammatory diseases. Therefore, this study aimed to evaluate the immune-modulating effects of the LPS-MSC-conditioned medium (CM) on V. cholerae LPS immunization in a murine model. After preconditioning MSCs with LPS, mice were immunized intraperitoneally on days 0 and 14 with the following combinations: LPS + LPS-MSC-CM; detoxified LPS (DLPS) + MSC-CM; LPS + MSC sup; LPS; LPS-MSC-CM; MSC supernatant (MSC sup); and PBS. The mouse serum and saliva samples were collected to evaluate antibody (serum IgG and saliva IgA) and cytokine responses (TNF-α, IL-10, IL-6, TGF-β, IL-4, IL-5, and B-cell activating factor (BAFF)). The LPS + LPS-MSC-CM significantly increased total IgG and IgA compared to other combinations (P &lt; 0.001). TNF-α levels, in contrast to IL-10 and TGF-β, were reduced significantly in mice receiving the LPS + LPS-MSC-CM compared to mice receiving only LPS. IL-4, IL-5, and BAFF levels significantly increased in mice receiving increased doses of LPS + LPS-MSC-CM compared to those who received only LPS. The highest vibriocidal antibody titer (1:64) was observed in LPS + LPS-MSC-CM-immunized mice and resulted in a significant improvement in survival in infant mice infected by V. cholerae O1. The LPS-MSC-CM modulates the immune response to V. cholerae LPS by regulating inflammatory and anti-inflammatory responses and inducing vibriocidal antibodies, which protect neonate mice against V. cholerae infection.</description><subject>Analysis</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Bacterial</subject><subject>Antibody</subject><subject>Antigens</subject><subject>Antimicrobial agents</subject><subject>BLyS protein</subject><subject>Cholera</subject><subject>Cholera toxin</subject><subject>Culture Media, Conditioned - pharmacology</subject><subject>Cytokine</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Flow cytometry</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunity</subject><subject>Immunization</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Interleukin 10</subject><subject>Interleukin 4</subject><subject>Interleukin 5</subject><subject>Interleukin 6</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>LPS</subject><subject>Lymphocytes B</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mesenchymal Stem Cells</subject><subject>Mice</subject><subject>Mitogens</subject><subject>Morbidity</subject><subject>Saliva</subject><subject>Septic shock</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transforming growth factors</subject><subject>Tumor necrosis factor-α</subject><subject>Vaccines</subject><subject>Vibrio cholerae</subject><subject>Vibrio cholerae O1</subject><issn>1757-6512</issn><issn>1757-6512</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkltr3DAQhU1paUKaP9CHYiiU9MGpLr6-FELoZSFQ6O1VjKXRWottbSU7dJ_7xzvOpuluqW3ZQvrmGJ05SfKcs0vO6_JN5FLUVcYEp1EKkbFHySmviiorCy4eH8xPkvMYN4wuKRkr86fJicwrKUTRnCa_VsMwj37wZu5h8mGXorWop5h6mw4YcdTdboA-jRMOqca-z7QfjZucH9EQYRykfkx7t_Vb3-8iaN1BcAYXge-uDc6nuvM9BsAUYgrpLSFuxFQD6RiY8FnyxEIf8fz-e5Z8e__u6_XH7ObTh9X11U2mS1FPWVW2tgBttalZIxhwkI1smppeFhhvaq0tMy2zCLWEoqhzrARCrnMoZC6sPEtWe13jYaO2wQ0QdsqDU3cLPqwVhMnpHpURwGXZNkbaOm9M1fKWoawLDqYqyDzServX2s4tmaBxnAL0R6LHO6Pr1Nrfqrooq6IsSeDiXiD4HzPGSQ0uLv7CiH6Oiroj6aEuEfryH3Tj5zCSVQvVUBCYkH-pNdAB3Gg9_VcvouqqrLmgJMiKqMv_UHQbHBx1Fq2j9aOC10cFxEz4c1rDHKNaffl8zL46YDuEfuqi7-clLPEYFHtQBx9jQPtgHGdqibfax1tRvNVdvBWjoheHlj-U_Amz_A2qyfSs</recordid><startdate>20211103</startdate><enddate>20211103</enddate><creator>Bahroudi, Mahboube</creator><creator>Bakhshi, Bita</creator><creator>Soudi, Sara</creator><creator>Najar-Peerayeh, Shahin</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7523-7905</orcidid></search><sort><creationdate>20211103</creationdate><title>Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate</title><author>Bahroudi, Mahboube ; Bakhshi, Bita ; Soudi, Sara ; Najar-Peerayeh, Shahin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Bacterial</topic><topic>Antibody</topic><topic>Antigens</topic><topic>Antimicrobial agents</topic><topic>BLyS protein</topic><topic>Cholera</topic><topic>Cholera toxin</topic><topic>Culture Media, Conditioned - pharmacology</topic><topic>Cytokine</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Flow cytometry</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunity</topic><topic>Immunization</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Interleukin 10</topic><topic>Interleukin 4</topic><topic>Interleukin 5</topic><topic>Interleukin 6</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>LPS</topic><topic>Lymphocytes B</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mesenchymal Stem Cells</topic><topic>Mice</topic><topic>Mitogens</topic><topic>Morbidity</topic><topic>Saliva</topic><topic>Septic shock</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transforming growth factors</topic><topic>Tumor necrosis factor-α</topic><topic>Vaccines</topic><topic>Vibrio cholerae</topic><topic>Vibrio cholerae O1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bahroudi, Mahboube</creatorcontrib><creatorcontrib>Bakhshi, Bita</creatorcontrib><creatorcontrib>Soudi, Sara</creatorcontrib><creatorcontrib>Najar-Peerayeh, Shahin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Stem cell research &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bahroudi, Mahboube</au><au>Bakhshi, Bita</au><au>Soudi, Sara</au><au>Najar-Peerayeh, Shahin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate</atitle><jtitle>Stem cell research &amp; therapy</jtitle><addtitle>Stem Cell Res Ther</addtitle><date>2021-11-03</date><risdate>2021</risdate><volume>12</volume><issue>1</issue><spage>564</spage><epage>564</epage><pages>564-564</pages><artnum>564</artnum><issn>1757-6512</issn><eissn>1757-6512</eissn><abstract>Vibrio cholerae is the causative agent of cholera, which is commonly associated with high morbidity and mortality, and presents a major challenge to healthcare systems throughout the world. Lipopolysaccharide (LPS) is required for full protection against V. cholerae but can induce inflammation and septic shock. Mesenchymal stem cells (MSCs) are currently used to treat infectious and inflammatory diseases. Therefore, this study aimed to evaluate the immune-modulating effects of the LPS-MSC-conditioned medium (CM) on V. cholerae LPS immunization in a murine model. After preconditioning MSCs with LPS, mice were immunized intraperitoneally on days 0 and 14 with the following combinations: LPS + LPS-MSC-CM; detoxified LPS (DLPS) + MSC-CM; LPS + MSC sup; LPS; LPS-MSC-CM; MSC supernatant (MSC sup); and PBS. The mouse serum and saliva samples were collected to evaluate antibody (serum IgG and saliva IgA) and cytokine responses (TNF-α, IL-10, IL-6, TGF-β, IL-4, IL-5, and B-cell activating factor (BAFF)). The LPS + LPS-MSC-CM significantly increased total IgG and IgA compared to other combinations (P &lt; 0.001). TNF-α levels, in contrast to IL-10 and TGF-β, were reduced significantly in mice receiving the LPS + LPS-MSC-CM compared to mice receiving only LPS. IL-4, IL-5, and BAFF levels significantly increased in mice receiving increased doses of LPS + LPS-MSC-CM compared to those who received only LPS. The highest vibriocidal antibody titer (1:64) was observed in LPS + LPS-MSC-CM-immunized mice and resulted in a significant improvement in survival in infant mice infected by V. cholerae O1. The LPS-MSC-CM modulates the immune response to V. cholerae LPS by regulating inflammatory and anti-inflammatory responses and inducing vibriocidal antibodies, which protect neonate mice against V. cholerae infection.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>34732259</pmid><doi>10.1186/s13287-021-02622-0</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7523-7905</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1757-6512
ispartof Stem cell research & therapy, 2021-11, Vol.12 (1), p.564-564, Article 564
issn 1757-6512
1757-6512
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d2a136b9d3f849d7b1b0e3851ad75473
source Publicly Available Content Database; PubMed Central
subjects Analysis
Animal models
Animals
Antibodies
Antibodies, Bacterial
Antibody
Antigens
Antimicrobial agents
BLyS protein
Cholera
Cholera toxin
Culture Media, Conditioned - pharmacology
Cytokine
Cytokines
Cytotoxicity
Drug dosages
Drug resistance
Flow cytometry
Humans
Immune response
Immunity
Immunization
Immunoglobulin A
Immunoglobulin G
Immunomodulation
Inflammation
Inflammatory diseases
Interleukin 10
Interleukin 4
Interleukin 5
Interleukin 6
Lipopolysaccharides
Lipopolysaccharides - pharmacology
LPS
Lymphocytes B
Medical research
Medicine, Experimental
Mesenchymal Stem Cells
Mice
Mitogens
Morbidity
Saliva
Septic shock
Stem cell transplantation
Stem cells
Transforming growth factors
Tumor necrosis factor-α
Vaccines
Vibrio cholerae
Vibrio cholerae O1
title Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A17%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunomodulatory%20effects%20of%20mesenchymal%20stem%20cell-conditioned%20media%20on%20lipopolysaccharide%20of%20Vibrio%20cholerae%20as%20a%20vaccine%20candidate&rft.jtitle=Stem%20cell%20research%20&%20therapy&rft.au=Bahroudi,%20Mahboube&rft.date=2021-11-03&rft.volume=12&rft.issue=1&rft.spage=564&rft.epage=564&rft.pages=564-564&rft.artnum=564&rft.issn=1757-6512&rft.eissn=1757-6512&rft_id=info:doi/10.1186/s13287-021-02622-0&rft_dat=%3Cgale_doaj_%3EA681251237%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c628t-76bf5acfcd80920a1a393998939fa0198ccf0db0fea83a5584e72ea4c4a5342f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2599132023&rft_id=info:pmid/34732259&rft_galeid=A681251237&rfr_iscdi=true